PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms

Cancer Cell

Volumn 3, Issue 2, 2003, Pages 117-130

  Freeman, Daniel J ^a   Li, Andrew G ^b   Wei, Gang ^b   Li, Heng Hong ^b   Kertesz, Nathalie ^a   Lesche, Ralf ^a,d   Whale, Andrew D ^b   Martinez Diaz, Hilda ^a   Rozengurt, Nora ^a   Cardiff, Robert D ^c   Liu, Xuan ^b   Wu, Hong ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d EPIGENOMICS AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P15; CYCLIN D1; GLUTATHIONE TRANSFERASE; MDM2 PROTEIN, HUMAN; MDM2 PROTEIN, MOUSE; NUCLEAR PROTEIN; ONCOPROTEIN; PHOSPHATASE; PROTEIN MDM2; PROTEIN P53; PTEN PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVITY; GENE ACTIVITY; GENE CONTROL; GENE MUTATION; GENETIC TRANSCRIPTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE; ANIMAL; CELL LINE; CHEMISTRY; CHROMATIN; FIBROBLAST; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOBLOTTING; METABOLISM; MOUSE MUTANT; NORTHERN BLOTTING; PHYSIOLOGY; SERODIAGNOSIS; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ANIMALIA;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE; CHROMATIN; CYCLIN D1; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FIBROBLASTS; GENE EXPRESSION REGULATION; GENES, TUMOR SUPPRESSOR; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOBLOTTING; MICE; MICE, KNOCKOUT; NUCLEAR PROTEINS; PHOSPHORIC MONOESTER HYDROLASES; PRECIPITIN TESTS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; PTEN PHOSPHOHYDROLASE; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0041450058     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00021-7     Document Type: Article

References (58)

1. Ackler S., Ahmad S., Tobias C., Johnson M.D., Glazer R.I. Delayed mammary gland involution in MMTV-AKT1 transgenic mice. Oncogene. 21:2002;198-206.
2. Bargonetti J., Manfredi J.J. Multiple roles of the tumor suppressor p53. Curr. Opin. Oncol. 14:2002;86-91.
3. Di Cristofano A., Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell. 100:2000;387-390.
4. Di Cristofano A., Pesce B., Cordon-Cardo C., Pandolfi P.P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19:1998;348-355.
5. Di Cristofano A., De Acetis M., Koff A., Cordon-Cardo C., Pandolfi P.P. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 27:2001;222-224.
6. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 10:1998;262-267.
7. Franke T.F., Kaplan D.R., Cantley L.C., Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science. 275:1997;665-668.
8. Freedman D.A., Levine A.J. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18:1998;7288-7293.
9. Fujisawa H., Reis R.M., Nakamura M., Colella S., Yonekawa Y., Kleihues P., Ohgaki H. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab. Invest. 80:2000;65-72.
10. Goberdhan D.C., Paricio N., Goodman E.C., Mlodzik M., Wilson C. Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev. 13:1999;3244-3258.
11. Groszer M., Erickson R., Scripture-Adams D.D., Lesche R., Trumpp A., Zack J.A., Kornblum H.I., Liu X., Wu H. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science. 294:2001;2186-2189.
12. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
13. Hill M., Hemmings B. Inhibition of protein kinase B/Akt. Implications for cancer therapy. Pharmacol. Ther. 93:2002;243-251.
14. Iijima M., Devreotes P. Tumor suppressor PTEN mediates sensing of chemoattractant gradients. Cell. 109:2002;599-610.
15. Jayaraman L., Freulich E., Prives C. Functional dissection of p53 tumor suppressor protein. Methods Enzymol. 283:1997;245-256. a.
16. Jayaraman L., Murthy K.G., Zhu C., Curran T., Xanthoudakis S., Prives C. Identification of redox/repair protein Ref-1as a potent activator of p53. Genes Dev. 11:1997;558-570. b.
17. Kamijo T., Zindy F., Roussel M.F., Quelle D.E., Downing J.R., Ashmun R.A., Grosveld G., Sherr C.J. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 91:1997;649-659.
18. Kato H., Kato S., Kumabe T., Sonoda Y., Yoshimoto T., Han S.Y., Suzuki T., Shibata H., Kanamaru R., Ishioka C. Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin. Cancer Res. 6:2000;3937-3943.
19. Koul A., Willen R., Bendahl P.O., Nilbert M., Borg A. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer. 94:2002;2369-2379.
20. Kurose K., Gilley K., Matsumoto S., Watson P., Zhou X.-P., Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat. Genet. 32:2002;355-357.
21. Lee J.O., Yang H., Georgescu M.M., Di Cristofano A., Maehama T., Shi Y., Dixon J.E., Pandolfi P., Pavletich N.P. Crystal structure of the PTEN tumor suppressor. implications for its phosphoinositide phosphatase activity and membrane association Cell. 99:1999;323-334.
22. Lesche R., Groszer M., Gao J., Wang Y., Messing A., Sun H., Liu X., Wu H. Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis. 32:2002;148-149.
23. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1997;1943-1947.
24. Li J., Simpson L., Takahashi M., Miliaresis C., Myers M.P., Tonks N., Parsons R. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res. 58:1998;5667-5672.
25. Li Y., Podsypanina K., Liu X., Crane A., Tan L.K., Parsons R., Varmus H.E. Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol. Biol. 2:2001;2.
26. Liaw D., Marsh D.J., Li J., Dahia P.L., Wang S.I., Zheng Z., Bose S., Call K.M., Tsou H.C., Peacocke M., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16:1997;64-67.
27. Ma H., Baumann C.T., Li H., Strahl B.D., Rice R., Jelinek M.A., Aswad D.W., Allis C.D., Hager G.L., Stallcup M.R. Hormone-dependent, CARM1-directed, arginine-specific methylation of histone H3 on a steroid-regulated promoter. Curr. Biol. 11:2001;1981-1985.
28. Macleod K.F., Jacks T. Insights into cancer from transgenic mouse models. J. Pathol. 187:1999;43-60.
29. Maehama T., Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273:1998;13375-13378.
30. Maehama T., Taylor G.S., Dixon J.E. PTEN and myotubularin. Novel phosphoinositide phosphatases Annu. Rev. Biochem. 70:2001;247-279.
31. Malstrom S., Tili E., Kappes D., Ceci J.D., Tsichlis P.N. Tumor induction by an Lck-MyrAkt transgene is delayed by mechanisms controlling the size of the thymus. Proc. Natl. Acad. Sci. USA. 98:2001;14967-14972.
32. Marsh D.J., Dahia P.L., Coulon V., Zheng Z., Dorion-Bonnet F., Call K.M., Little R., Lin A.Y., Eeles R.A., Goldstein A.M., et al. Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation. Genes Chromosomes Cancer. 21:1998;61-69.
33. Mayo L.D., Donner D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. USA. 98:2001;11598-11603.
34. Mayo L., Donner D. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem. Sci. 27:2002;462-467.
35. Mayo L.D., Dixon J.E., Durden D.L., Tonks N.K., Donner D.B. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 277:2002;5484-5489.
36. Myers M.P., Tonks N.K. Pten. sometimes taking it off can be better than putting it on Am. J. Hum. Genet. 61:1997;1234-1238.
37. Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P., Hemmings B.A., Wigler M.H., Downes C.P., Tonks N.K. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl. Acad. Sci. USA. 95:1998;13513-13518.
38. Nelen M.R., van Staveren W.C., Peeters E.A., Hassel M.B., Gorlin R.J., Hamm H., Lindboe C.F., Fryns J.P., Sijmons R.H., Woods D.G., et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum. Mol. Genet. 6:1997;1383-1387.
39. Nie Y., Li H.H., Bula C.M., Liu X. Stimulation of p53 DNA binding by c-Abl requires the p53 C terminus and tetramerization. Mol. Cell. Biol. 20:2000;741-748.
40. Ogawara Y., Kishishita S., Obata T., Isazawa Y., Suzuki T., Tanaka K., Masuyama N., Gotoh Y. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J. Biol. Chem. 277:2002;21843-21850.
41. Podsypanina K., Ellenson L.H., Nemes A., Gu J., Tamura M., Yamada K.M., Cordon-Cardo C., Catoretti G., Fisher P.E., Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA. 96:1999;1563-1568.
42. Rasheed B.K., Stenzel T.T., McLendon R.E., Parsons R., Friedman A.H., Friedman H.S., Bigner D.D., Bigner S.H. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 57:1997;4187-4190.
43. Schwertfeger K.L., Richert M.M., Anderson S.M. Mammary gland involution is delayed by activated Akt in transgenic mice. Mol. Endocrinol. 15:2001;867-881.
44. Sheng X., Koul D., Liu J.L., Liu T.J., Yung W.K. Promoter analysis of tumor suppressor gene PTEN. identification of minimum promoter region Biochem. Biophys. Res. Commun. 292:2002;422-426.
45. Simpson L., Parsons R. Pten. life as a tumor suppressor Exp. Cell Res. 264:2001;29-41.
46. Stambolic V., MacPherson D., Sas D., Lin Y., Snow B., Jang Y., Benchimol S., Mak T.W. Regulation of PTEN transcription by p53. Mol. Cell. 8:2001;317-325.
47. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Siderovski D.P., Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 95:1998;29-39.
48. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15:1997;356-362.
49. Stiles B., Gilman V., Khanzenzon N., Lesche R., Li A., Qiao R., Liu X., Wu H. Essential role of AKT-1/protein kinase B alpha in PTEN-controlled tumorigenesis. Mol. Cell. Biol. 22:2002;3842-3851.
50. Stocker H., Andjelkovic M., Oldham S., Laffargue M., Wymann M.P., Hemmings B.A., Hafen E. Living with lethal PIP3 levels. viability of flies lacking PTEN restored by a PH domain mutation in Akt/PKB Science. 295:2002;2088-2091.
51. Sun H., Lesche R., Li D.M., Liliental J., Zhang H., Gao J., Gavrilova N., Mueller B., Liu X., Wu H. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/ protein kinase B signaling pathway. Proc. Natl. Acad. Sci. USA. 96:1999;6199-6204.
52. Suzuki A., de la Pompa J.L., Stambolic V., Elia A.J., Sasaki T., del Barco Barrantes I., Ho A., Wakeham A., Itie A., Khoo W., et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8:1998;1169-1178.
53. Wu X., Senechal K., Neshat M.S., Whang Y.E., Sawyers C.L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA. 95:1998;15587-15591.
54. Xiao A., Wu H., Pandolfi P.P., Louis D.N., Van Dyke T. Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell. 1:2002;157-168.
55. Yamada K.M., Araki M. Tumor suppressor PTEN. modulator of cell signaling, growth, migration and apoptosis J. Cell Sci. 114:2001;2375-2382.
56. You M.J., Castrillon D.H., Bastian B.C., O'Hagan R.C., Bosenberg M.W., Parsons R., Chin L., DePinho R.A. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc. Natl. Acad. Sci. USA. 99:2002;1455-1460.
57. Zhou B.P., Hung M.C. Novel targets of Akt, p21(Cipl/WAF1), and MDM2. Semin. Oncol. 29:2002;62-70.
58. Zhou B.P., Liao Y., Xia W., Zou Y., Spohn B., Hung M.C. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3:2001;973-982.